2. Academic Validation
  3. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer

Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer

  • Anticancer Res. 2019 Apr;39(4):1767-1775. doi: 10.21873/anticanres.13283.
Eisuke Kurihara 1,  Kazuhiko Shien 2,  Hidejiro Torigoe 1,  Tatsuaki Takeda 3,  Yuta Takahashi 1,  Yusuke Ogoshi 1,  Takahiro Yoshioka 4,  Kei Namba 1,  Hiroki Sato 1,  Ken Suzawa 1,  Hiromasa Yamamoto 1,  Junichi Soh 1,  Mikio Okazaki 1,  Tadahiko Shien 1,  Shuta Tomida 5,  Shinichi Toyooka 1
Affiliations

Affiliations

  • 1 Department of Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • 2 Department of Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan [email protected].
  • 3 Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • 4 Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • 5 Biobank, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
PMID: 30952716 DOI: 10.21873/anticanres.13283
Abstract

Background: The 90-kDa heat-shock protein (HSP90) is a chaperone protein expressed at high levels in Cancer cells and is involved in the folding or stabilization of several client proteins, including epidermal growth factor receptor (EGFR). Ganetespib is a second-generation HSP90 Inhibitor with a potent antitumor effect against various Cancer types.

Materials and methods: This study examined the antitumor effect of ganetespib in EGFR-mutant non-small cell lung Cancer (NSCLC) cells and experimentally established EGFR-tyrosine kinase inhibitor (TKI)-resistant cells harboring various resistance mechanisms, including EGFR T790M mutation, met proto-oncogene amplification, and epithelial-mesenchymal transition.

Results: Ganetespib showed a potent antitumor effect at low concentrations, suppressing EGFR-related downstream pathway molecules and inducing cleavage of poly ADP-ribose polymerase in all examined EGFR-TKI-resistant cell lines in vitro. Ganetespib also inhibited in vivo tumor growth in resistant cells harboring EGFR T790M.

Conclusion: Ganetespib might be a promising therapeutic option for the treatment of patients with EGFR-TKI-resistant NSCLC.

Keywords

EGFR-TKI; HSP90 inhibitor; acquired drug resistance; ganetespib; non-small cell lung cancer.

Figures
Products